Tyking over… nicely
Sareum’s investment case centres on the development and potential out-licensing of its two internal, preclinical-stage TYK2/JAK1 inhibitors, which are proceeding towards IND (investigational new drug) filings in 2020. Development of Sareum’s Chk1 inhibitor, SRA737, is ongoing for now, but is likely to see a pause, while Sareum’s partner, Sierra Oncology, attempts to secure a sub-licensing deal following a change in its own strategic priorities. The uncertainty created by this decision has weighed on Sareum’s share price, despite trials of SRA737 yielding some promising early data and highlighting a fast-to-market development plan.
Sareum Holdings is a holding company. Through its subsidiary, Co. is engaged as a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Co.'s drug development pipeline includes: Chk1 (SRA737), which targets genetically defined solid cancers; TYK2, which targets autoimmune diseases and cancer; and Aurora+FLT3, which targets Acute Myeloid Leukemia and other blood cancers.
QuotedData you with provides access to research on Investment Companies, Investment Trusts and Mining companies. Our aim is to provide you all the information you might need to make your own investment decisions. We cannot offer you advice on your investments.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.